{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:51:30Z","timestamp":1790801490983,"version":"4.1.0"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T00:00:00Z","timestamp":1658966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Atopic dermatitis (AD) is a chronic recurrent inflammatory disease, and dupilumab, a human monoclonal antibody, is the firstly approved biological drug for AD. Psoriasiform erythema (PE) during dupilumab treatment in adults has been reported. This study describes the risk of PE in children after initiation of dupilumab treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>\n                      To evaluate the\n                      <jats:italic>de novo<\/jats:italic>\n                      cytokines gene expression in the transition of atopic dermatitis symptoms to psoriasiform erythema during dupilumab treatment in children.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Two 17-year-old teenage twin patients with AD were included in this study who developed psoriasiform erythema after initiation of dupilumab. The lesional skin biopsy specimens were obtained for the histopathological investigation and RNA Fluorescence\n                      <jats:italic>In Situ<\/jats:italic>\n                      Hybridization (RNA-FISH). Dermoscopy, cytometry (cytokine detection in the blood), and blood investigations were completed for the pedigree and the lesioned descriptions.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Two twin patients with AD presented with erythematic scaly plaques on the back, scalp, abdomen, and extensor extremities after 20 weeks of dupilumab treatment. The transitional change of AD to psoriasiform erythema treated with dupilumab was observed. Our subjects' dermoscopy showed pinpoint bleeding and white scales on pink background. Histopathology features showed psoriasiform hyperplasia, epidermal hyperplasia (acanthosis), ectatic capillaries, perivascular lymphocytes infiltration, and parakeratosis, with the absence of the granular cell layer. mRNA (RNA-FISH) cytokines gene expression showed a significantly high concentration of IL-17A. Blood investigation results showed a high concentration of (Immunoglobulin E) IgE and Eosinophils, and cytokines detection in blood showed IL-5,6 and IL-17 in one patient; however, only IL-5 in another patient. The dupilumab was discontinued and initiated with Baricitinib. Baricitinib showed a significant reduction in skin lesions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Psoriasiform erythema can appear during dupilumab treatment in atopic dermatitis children. Potently, by suppressing skewed Th2 activation in patients with AD, the balance might shift toward Th1\/Th17 predominance, and psoriasis develops. Baricitinib is a potential drug for psoriasiform erythema with significant therapeutic effects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2022.932766","type":"journal-article","created":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T02:19:40Z","timestamp":1658974780000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":25,"title":["Case report: Clinical and histopathological characteristics of psoriasiform erythema and de novo IL-17A cytokines expression on lesioned skin in atopic dermatitis children treated with dupilumab"],"prefix":"10.3389","volume":"9","author":[{"given":"Kamran","family":"Ali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liming","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YunMi","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menghua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S0140-6736(20)31286-1","article-title":"Atopic dermatitis","volume":"396","author":"Langan","year":"2020","journal-title":"Lancet."},{"key":"B2","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1056\/NEJMoa1314768","article-title":"Dupilumab treatment in adults with moderate-to-severe atopic dermatitis","volume":"371","author":"Beck","year":"2014","journal-title":"N Engl J Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1001\/jamadermatol.2021.3023","article-title":"Simpson EL. Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial","volume":"157","author":"Blauvelt","year":"2021","journal-title":"JAMA Dermatol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2147\/BTT.S195512","article-title":"Dupilumab side effect in a patient with atopic dermatitis: a case report study","volume":"13","author":"Albader","year":"2019","journal-title":"Biologics."},{"key":"B5","doi-asserted-by":"publisher","first-page":"181","DOI":"10.4168\/aair.2016.8.3.181","article-title":"Comprehensive review of the treatment of atopic eczema","volume":"8","author":"Lee","year":"2016","journal-title":"Allergy Asthma Immunol Res."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-018-0001-z","article-title":"Atopic dermatitis","volume":"4","author":"Weidinger","year":"2018","journal-title":"Nat Rev Dis Primers."},{"key":"B7","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.jdcr.2018.05.014","article-title":"Erythrodermic presentation of psoriasis in a patient treated with dupilumab JAAD","volume":"4","author":"Tracey","year":"2018","journal-title":"Case Rep."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e12998","DOI":"10.1111\/dth.12998","article-title":"A case of guttate psoriasis during treatment with dupilumab","volume":"32","author":"Gori","year":"2019","journal-title":"Dermatol Ther."},{"key":"B9","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1097\/DER.0000000000000509","article-title":"Psoriasis-like dermatitis developing in a patient with atopic dermatitis treated with dupilumab","volume":"30","author":"Stout","year":"2019","journal-title":"Dermatitis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1097\/DER.0000000000000481","article-title":"Psoriasiform dermatitis after initiation of treatment with dupilumab for atopic dermatitis","volume":"30","author":"Fowler","year":"2019","journal-title":"Dermatitis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1111\/pde.14820","article-title":"Paller AS. Psoriasiform dermatitis during dupilumab treatment for moderate-to-severe atopic dermatitis in children","volume":"38","author":"Parker","year":"2021","journal-title":"Pediatr Dermatol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.coi.2017.08.008","article-title":"Atopic dermatitis and psoriasis: two different immune diseases or one spectrum?","volume":"48","author":"Guttman-Yassky","year":"2017","journal-title":"Curr Opin Immunol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1080\/09546634.2016.1230173","article-title":"Eczema as an adverse effect of anti-TNF\u03b1 therapy in psoriasis and other Th1-mediated diseases: a review","volume":"28","author":"Nakamura","year":"2017","journal-title":"J Dermatolog Treat."},{"key":"B14","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1111\/bjd.20064","article-title":"Dupilumab-induced phenotype switch from atopic dermatitis to psoriasis is characterized by de novo interleukin-17A expression: a case report","volume":"185","author":"Mirza","year":"2021","journal-title":"Br J Dermatol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1016\/j.jaci.2015.08.015","article-title":"The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization","volume":"136","author":"Noda","year":"2015","journal-title":"J Allergy Clin Immunol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1080\/09546634.2019.1577549","article-title":"JAK\/STAT inhibitors for the treatment of atopic dermatitis","volume":"31","author":"Rodrigues","year":"2020","journal-title":"J Dermatolog Treat."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1080\/14656566.2017.1378343","article-title":"Small molecule therapy for managing moderate to severe psoriatic arthritis","volume":"18","author":"Costa","year":"2017","journal-title":"Expert Opin Pharmacother."},{"key":"B18","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.jaad.2016.12.005","article-title":"inhibitors in dermatology: The promise of a new drug class","volume":"76","author":"Damsky","year":"2017","journal-title":"J Am Acad Dermatol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.jaci.2021.08.009","article-title":"inhibitors in the treatment of atopic dermatitis","volume":"148","author":"Chovatiya","year":"2021","journal-title":"J Allergy Clin Immunol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s13555-019-00347-w","article-title":"Systemic treatment of psoriasis with JAK inhibitors: a review","volume":"10","author":"Kvist-Hansen","year":"2020","journal-title":"Dermatol Ther (Heidelb)."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.932766\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T02:19:44Z","timestamp":1658974784000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.932766\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,28]]},"references-count":20,"alternative-id":["10.3389\/fmed.2022.932766"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.932766","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,28]]},"article-number":"932766"}}